

**Preliminary Scientific Program
As of October 25, 2018**

Plenary Session	Parallel Session	Oral Presentation Session	Industry Session	Break
------------------------	-------------------------	----------------------------------	-------------------------	--------------

Wednesday, 20 February 2019

14:30-16:00	PARALLEL INDUSTRY SYMPOSIUM	PARALLEL INDUSTRY WORKSHOP		PARALLEL INDUSTRY SYMPOSIUM
16:15-17:45	PARALLEL INDUSTRY WORKSHOP	PARALLEL INDUSTRY WORKSHOP	PARALLEL INDUSTRY WORKSHOP	PARALLEL INDUSTRY WORKSHOP
18:00-19:00	OPENING CEREMONY			
	Tadej Battelino - Opening Remarks			
	Lutz Heinemann – Future of Diabetes Technology – where are we going from here?			
19:00-20:00	NETWORKING RECEPTION (In the Exhibition Area)			

Thursday, 21 February 2019

08:30-10:00	PLENARY SESSION DECISION SUPPORT SYSTEMS (DSS)					
	<p>Rich Bergenstal- Do we need diabetes decision support systems?</p> <p>Bruce Bode - Use of Decision Support System in the Hospital</p> <p>Moshe Phillip - Advice4U – Decision Support Systems for healthcare professionals</p> <p>Courtney Lias – Regulatory aspects of the use of Decision Support Systems</p>					
10:00-10:30	COFFEE BREAK					
10:30-12:00	PLENARY INDUSTRY SYMPOSIUM					
12:00-13:00	LUNCH BREAK					
13:00-14:30	PARALLEL SESSION NEW AVENUES IN PROTEIN DRUGS FOR DIABETES	PARALLEL SESSION TIME IN RANGES (TIRs)	PARALLEL SESSION NUTRITION AND FOOD TECHNOLOGY	JDRF PARALLEL SESSION TOWARD NEXT- GENERATION PHYSIOLOGIC AUTOMATED INSULIN DELIVERY (AID) SYSTEMS: A PROMISING FRONTIER	PARALLEL INDUSTRY	PARALLEL INDUSRY

	<p>Cliff Bailey - Targeting more than one receptor</p> <p>Melanie Davies - Oral absorption of protein drugs</p> <p>Tim Heise - Smart insulins</p> <p>Jessica Castle - Stable Glucagon</p>	<p>Simon Heller - Exploring and explaining the rationale for a new and extending classification of hypoglycemia in an era of CGM</p> <p>Roy Beck - Time in Range as an outcome in clinical trials</p> <p>Irl Hirsch – Time in Range(s) vs. HbA1c: Are Our Patients Ready to Change?</p> <p>Tadej Battelino – Time in Range – towards a consensus</p>	<p>Ram Weiss - personalized nutrition: the time has come?</p> <p>Michal Gillon - Complementary sensors technologies for food consumption monitoring</p> <p>Andrea Scaramuzza - Efficacy of an app to count carbs to limit the post-meal glucose rise in children with type 1 diabetes</p>	<p>Jaime Giraldo - JDRF Strategy and Perspective</p> <p>Eric Renard - Current Status of Physiologic Insulin Delivery: Clinical Benefits and Challenges</p> <p>Eyal Dassau - Algorithms for Automated Delivery of Insulin in the Intraperitoneal (IP) Space</p> <p>Guillermo Arreaza-Rubin - Implantable IP AID Systems: Assessment of Needs</p> <p>Jackie Le Grand - Opportunities and Challenges in Adoption of and Access to Implantable IP AID Systems</p> <p>Moderated Panel Q&A Moderator - Daniel Finan Panel - Eric Renard, Eyal Dassau, Guillermo Arreaza-Rubin, Katharine Barnard, Anne Nordyke, Greg Peterson</p>		
--	---	--	--	---	--	--

14:30-15:00	COFFEE BREAK
-------------	--------------

15:00-16:30	PLENARY INDUSTRY SYMPOSIUM
-------------	----------------------------

16:40- 18:00	PARALLEL SESSION COGNITION IN DIABETES	PARALLEL SESSION NOVEL BIOMARKERS FOR DIABETES	PARALLEL SESSION CLOSED-LOOP SYSTEMS – WHERE ARE WE NOW?	PARALLEL INDUSTRY	ORAL 1	ORAL 2
	<p>Pratik Choudhary – Impact of hypoglycemia on cognitive function</p> <p>Jasna Šuput Omladič – Impact of Hyperglycemia on cognitive function</p> <p>Stuart Weinzimer - Brain and cognitive consequences of type 1 diabetes (T1D) – the DirecNet Project</p> <p>Stephanie Amiel - Hypo in clinical trials and vice-versa</p>	<p>Lorena Wright - Novel Diabetes Biomarkers: An Update of 1,5 AG for the Clinician</p> <p>Marcello Ciaccio - Glycated Albumin: from biochemistry to clinical applications</p> <p>Markus Stoffel- non-codingRNA in Diabetes</p> <p>Desmond Schatz – Novel Biomarkers identified by international prevention-studies</p>	<p>Bruce Bode - Outcomes of the Medtronic 670G in diabetes clinics in the USA</p> <p>Roman Hovorka – Progress on using Cambridge Closed-Loop algorithm</p> <p>Eyal Dassau – Harvard's experience with closed-loop</p> <p>Sue Brown – Virginia's experience with closed-loop</p> <p>Tadej Battelino – update from the FLAIR study</p> <p>Ahmad Haidar – Pramlintide in the artificial pancreas</p> <p>John Pickup - values vs. affordability of diabetes technology</p>			

Friday, 22 February 2019

08:00-08:50	PLENARY INDUSTRY MORNING SYMPOSIUM					
09:00- 10:00	PARALLEL SESSION NEW MODELS OF IMPLEMENTING CGM	PARALLEL SESSION ADJUNCTIVE THERAPIES FOR T1D	PARALLEL SESSION PSYCHOLOGICAL INTERVENTION TO INCREASE THE USE OF TECHNOLOGY BY T1D PATIENTS	Oral 3	PARALLEL INDUSTRY	PARALLEL INDUSTRY
	<p>Tom Martens – CGM use in a primary care network</p> <p>Amit Majithia - CGM for type 2 diabetes – direct to consumer</p> <p>Roy Beck – CGM use for type 1 diabetes – direct to consumer</p>	<p>Satish Garg – Emerging role of Adjunctive Therapies for T1D</p> <p>Chantal Mathieu - The concept of SGLT in diabetes</p> <p>Thomas Danne - Report on the consensus on SGLT in T1D</p>	<p>Alon Liberman - Introduction</p> <p>Susana R. Patton - Adherence to Insulin Pump Behaviors in Young Children with Type 1 Diabetes Mellitus: Opportunities for Intervention</p> <p>Katharine Barnard - Psychosocial Aspects & Diabetes Technology- Head to Head or Hand in Hand?</p> <p>Korey Hood - Preventing poor psychosocial and glycemic outcomes in teens with type 1 diabetes</p>			
10:00-10:30	COFFEE BREAK					
10:30-12:00	PLENARY INDUSTRY SYMPOSIUM					
12:00-13:00	LUNCH BREAK					
13:00-14:30	PLENARY SESSION - ATTD YEARBOOK					

14:30-15:00	COFFEE BREAK					
15:00-16:30	PLENARY INDUSTRY SYMPOSIUM					
16:40- 18:10	PARALLEL SESSION PATIENT DECISION SUPPORT: CONCEPT AND TOOLS	PARALLEL SESSION PATIENT-REPORTED OUTCOME MEASURES (PROMS) AND OUTCOME DRIVEN MEDICINE	PARALLEL SESSION DIABETES EDUCATION	Parallel industry	Parallel Industry	Parallel Industry
	<p>Boris Kovatchev - Decision support system for patients with diabetes: concept, goals and feasibility</p> <p>Pau Herrero - A better care for diabetes</p> <p>Lutz Heinemann - Integrated Personalized Diabetes Management: Results of the Pro Value Studies</p> <p>Revital Nimri - Decision Support Systems directly to the patients</p>	<p>Katharine Barnard - Evaluation of Patient-Reported Outcome Measures (PROMs).</p> <p>Neal Kaufman – Evidence-based behavior change intervention</p> <p>Michael Riddell – PROMs, Apps and Exercise in Diabetes</p> <p>Mark Palmert - A Mobile App for the Self-Management of Type 1 Diabetes Among Adolescents: A Randomized Controlled Trial</p>	<p>Andrea Scaramuzza - Education in Predictive Low Glucose Management (<i>PLGM</i>)</p> <p>Debate: What is more important:</p> <p>Lori Laffel - Structured education</p> <p>Hood Thabit: Diabetes Technology (closed-loop)</p> <p>Laurel Messer - The importance of education in Closed-loop</p> <p>Goran Petrovski - Education through Facebook and other social media</p>			

Saturday, 23 February 2019

<p>08:30-10:00</p>	<p>PARALLEL SESSION THERAPIES IN TYPE 2 DIABETES</p>	<p>PARALLEL SESSION WHAT PATIENTS DO WITH CGM DATA AND WHAT THEY SHOULD DO</p>	<p>PARALLEL SESSION DATA DIABETES SCIENCE</p>	<p>ORAL 4</p>	<p>ORAL 5</p>
	<p>Richard Bergenstal – Does MDI therapy really work in T2D</p> <p>Nebojsa Lalic - Pumps in T2D</p> <p>Jane Reusch - Add on to basal insulin: patient centered considerations</p> <p>Oliver Schnell - The role of AbA1c point of care testing in the management of diabetes and cardiovascular disease</p>	<p>Norbert Hermanns - Medical Need for training courses for patients to make optimal usage of CGM (rtCGM and iscCGM)</p> <p>Hans DeVries - CGM for hypoglycemia-prone patients</p> <p>Gérard Reach - Decisions in the psychology of glucose monitoring</p>	<p>Philip Bourne - The Five Pillars of Health Data Science – An Introduction</p> <p>Howard Zisser - The Connected Patient</p> <p>Eyal Dassau - Adaptive Automated Control of Diabetes – the Ultimate Personalized Diabetes Treatment</p> <p>Boris Kovatchev - Building a virtual image of patient – the VIP approach to precision medicine for diabetes</p>		
<p>10:00-10:30</p>	<p>COFFEE BREAK</p>				

10:30- 11:30	PARALLEL SESSION ULTRA RAPID ACTING INSULINS AND TECHNOLOGY	ISPAD PARALLEL SESSION DIABETES TECHNOLOGY IN PEDIATRICS: ISPAD GUIDELINES UPDATE AND THE FUTURE	PARALLEL SESSION DO IT YOURSELF IN DIABETES	ORAL 6
	<p>David Klonoff – Rapid Acting Insulin in CSII</p> <p>Bruce Bode - Ultra Rapid acting insulin in Closed-Loop systems</p> <p>Klemen Dovc – Rapid Acting Insulin, exercise and Closed-Loop</p>	<p>Jennifer Sherr - Insulin pumps</p> <p>Martin de Bock - Continuous glucose monitoring</p> <p>Martin Tauschmann - Sensor augmented pump, hybrid closed loop, closed-loop</p>	<p>Aaron Kowalski – Interoperable and Do-It-Yourself systems</p> <p>Lenka Petruzelkova - The European perspective of DIY for Closed-Loop</p> <p>Dana Lewis – "#WeAreNotWaiting: DIY Diabetes Data & Research</p>	
11:30-12:30	PLENARY SESSION BETA CELL REPLACEMENT STRATEGIES 2019			
	<p>Pratik Chaudhary - Future of Islet transplantation, latest outcomes and who should be referred</p> <p>Lorenzo Piemonti – Future Landscape: Defining a successful outcome using stem cells as a source of insulin producing cells</p> <p>Jay Skyler - Beta cell replacement 2019 and beyond</p>			
12:00-12:35	CLOSING REMARKS AND FAREWELL – Moshe Phillip			
12:35-13:20	FAREWELL REFRESHMENTS (Exhibition Area)			